Recent research have focused on the intersection of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR activator therapies and dopamine neurotransmission. While GLP activators are increasingly employed for treating type 2 diabetes, their emerging effects on motivation circu